Polatuzumab vedotin(Pola)is a novel antibody-drug conjugate targeting CD79b, which has been shown to be effective in treating newly diagnosed and relapsed/refractory diffuse large B cell lymphoma(DLBCL)during clinical trials. This evidence concerns the gene POLA1 and diffuse large B-cell lymphoma.